###### Strengths and limitations of this study

-   Prospective cohort study over 10 years to identify risk factors for needing long-term care.

-   Relationships between muscle mass, muscle strength or insulin sensitivity and multiple diseases necessitating long-term care will be evaluated simultaneously.

-   A relatively large cohort was assembled for evaluating muscle mass, muscle strength, insulin sensitivity, whole brain MRI, cognitive function, vascular function, physical fitness and knee osteoarthritis, simultaneously.

-   Study results may suggest novel strategies to prevent the need for long-term care.

-   This study has several limitations: (1) including only participants living in an urban part of Japan, (2) challenges in confirming causal relationships and (3) a relatively low participants rate (18.9%).

Introduction {#s1}
============

The number of elderly people (aged ≥65 years) has increased worldwide. For example, WHO defined the ageing rate as proportion of persons aged 65 years or older. The ageing rate has been increasing in both developed and low/middle-income countries. In 2015, the worldwide ageing rate was 8.3% and it is estimated to increase to 17.8% by 2055. While the ageing rate in developed countries is predicted to reach 27.8% in 2060,[@R1] the ageing rate in Japan reached 27.7% in 2017[@R2]; it is the highest in the world. Japan is now categorised as a super-aged society, defined as a country with an ageing rate greater than 21%.[@R3] The rate will reach 30% in 2025 and 40% in 2060. A serious social problem in such a super-aged society is the increase in the number of elderly people who need long-term care. Need for long-term care is defined as a condition where an elderly individual needs care to perform activities of daily living due to age-related diseases such as cerebrovascular disease, dementia and musculoskeletal disease. The number of individuals who need long-term care in Japan increased from 2.18 million in 2000 to 6.06 million in 2015. Social security expenses for long-term care increased from JP¥3.6 trillion in 2000 to JP¥10.1 trillion in 2015.[@R5] These figures are predicted to increase and cause increased social and economic burden in Japan. Thus, the Japanese government has launched a policy to extend healthy life expectancy without long-term care[@R7]; however, evidence-based strategies to prevent the need for long-term care have not been established yet.

In Japan, the main causes of needing long-term care are cerebrovascular disease (17.2%), dementia (16.4%), age-related frailty (13.9%), falls and fractures (12.2%) and joint disease (11.0%).[@R2] Thus, multiple approaches to prevent these diseases will be useful for preventing the need for long-term care. However, if there are common risk factors for the onset of these diseases, it would be helpful to find an efficient strategy to prevent the need for long-term care. Several previous studies have demonstrated that a decrease in muscle mass or muscle strength[@R8] or insulin sensitivity[@R19] may be common risk factors for diseases related to needing long-term care. Indeed, aging-related decreases in muscle strength or muscle mass[@R8] are associated with an increased risk for metabolic syndrome,[@R10] cognitive decline,[@R12] cerebrovascular disease[@R27] and all-cause mortality.[@R13] In addition, decreased muscle mass or muscle strength is also closely associated with decreased mobility, falls and fractures[@R15] as well as decreased psychosocial well-being[@R17] and quality of life,[@R18] which are associated with geriatric depression. On the other hand, impaired insulin sensitivity is associated with cardiovascular disease[@R19] and lacunar infarcts[@R21] as well as microstructural white matter changes[@R23] and decreased cognitive performance.[@R24] Given that skeletal muscle is the main organ that determines whole-body insulin sensitivity,[@R30] we hypothesised that parameters related to muscle function such as muscle mass, muscle strength and insulin sensitivity might be the common risk factors for diseases related to needing long-term care. However, there is insufficient clinical evidence to support this hypothesis.

On the other hand, several other risk factors for diseases related to needing long-term care have been reported. For example, arteriosclerosis determined by Cardio-Ankle Vascular Index (CAVI) predicts cognitive decline in elderly Japanese individuals.[@R32] A recent meta-analysis showed a modest association between CAVI and incident cardiovascular disease risk.[@R33] In addition, cerebral small vessel disease (SVD), defined as lacunar infarcts, cerebral microhaemorrhages, periventricular hyperintensities (PVHs) or deep and subcortical white matter hyperintensities (DSWMHs) detected on MRI, is strongly associated with incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality.[@R34] Furthermore, a meta-analysis of data from 12 cohort studies showed that low hip bone mineral density (BMD) is an important predictor of fracture risk.[@R35] We hypothesised that muscle mass, muscle strength and insulin sensitivity are also common risk factors for arteriosclerosis, cerebral SVD and lower BMD; however, this hypothesis has not been tested yet.

In this context, we developed a prospective cohort study of elderly individuals in an urban community. The primary objective of the present study is to prospectively investigate associations between muscle mass, muscle strength or insulin sensitivity and main causes and risk factors for needing long-term care. The primary outcomes of the present study are incidence of cerebrovascular disease and cognitive decline. Secondary outcomes are incidence of age-related frailty, falls and fractures, and joint disease, respectively.

Cohort description {#s2}
==================

Study design {#s2-1}
------------

The Bunkyo Health Study is a prospective cohort study of over 10 years. We recruited elderly subjects aged 65--84 years living in Bunkyo-ku, an urban area in Tokyo, Japan ([figure 1](#F1){ref-type="fig"}). Bunkyo-ku was selected because the age distribution in Bunkyo-ku is similar to that of Tokyo overall and there is high accessibility to the research centre. Among 68 communities in Bunkyo-ku, we selected 13 communities based on probability proportionate to size sampling. We obtained the name and address of all residents aged 65--84 years in the selected communities from residential registries. We mailed invitations to a group briefing session at our institution (Sportology Center, Juntendo University). The inclusion criterion of the present study was age of 65--84 years. The exclusion criteria were pacemaker or defibrillator placement and diabetes requiring insulin therapy. After the briefing session, subjects who provided written informed consent were included as research participants. The primary outcomes of the present study are incidence of cerebrovascular disease and cognitive decline. The secondary outcomes are age-related frailty, falls and fractures, and joint disease. The exploratory outcomes are arteriosclerosis, cerebral SVD and osteoporosis as well as cognitive function, brain volume and structure, depression, physical function and all-cause mortality.

![Geographical location of Bunkyo-ku in Japan. Left: Japan is divided into 47 prefectures. The location of Tokyo is indicated by a circle. Centre: Tokyo is a prefecture that includes 23 special wards, 26 cities, 5 towns and 8 villages. Bunkyo is one of the special wards (Bunkyo-ku in Japanese). It located in east Tokyo, as indicated by the circle. Right: Bunkyo-ku includes 68 communities and has 227 902 residents (source of map; <http://www.start-point.net>).](bmjopen-2019-031584f01){#F1}

The study protocol is outlined in [figure 2](#F2){ref-type="fig"}. All subjects participated in examinations over two visits to the Sportology Center. During the first visit, subjects participated in cognitive function[@R36] and physical fitness testing.[@R38] MRI of the whole brain and the knee of the dominant leg or the leg with pain was performed. We also interviewed subjects about their medical history, family history and current pain. During the second visit, we evaluated body composition and BMD using dual-energy X-ray absorptiometry (DXA),[@R43] CAVI[@R44] and abdominal fat distribution with MRI after an overnight fast.[@R45] Next, we carried out a 75 g oral glucose tolerance test (OGTT).[@R46] All data were collected and stored at the Sportology Center.

![Experimental protocol.](bmjopen-2019-031584f02){#F2}

After the baseline evaluation (15 October 2015 to 1 October 2018), we will ask participants about their health status every year by mail. For example, we will ask about incidence of cerebrovascular disease, falls, fractures and other diseases every year. We also will send the Kihon Checklist questionnaire[@R47] to participants every year. This questionnaire was developed to identify elderly individuals with frailty or at high risk for needing long-term care. It consists of 25 questions regarding instrumental and social activities of daily living, physical function, nutritional status, oral function, cognitive function and depressed mood.[@R47] At 5 years (2020--2023) and 10 years (2025--2028) after the baseline examination, we are planning to re-evaluate cognitive function, brain MRI parameters and other parameters measured at baseline except OGTT.

Sample size calculations {#s2-2}
------------------------

Since the primary outcomes are incidence of cerebrovascular disease and cognitive decline and the incidence of cognitive decline is lower than the incidence of cerebrovascular disease,[@R49] the sample size was calculated to allow for evaluation of associations between cognitive decline and muscle mass, muscle strength and insulin sensitivity, respectively. Cognitive decline was defined as the presence of dementia or mild cognitive impairment (MCI) estimated using the Montreal Cognitive Assessment (MoCA), Japanese version[@R36] or the Mini-Mental State Examination (MMSE),[@R37] respectively. In the prospective analysis, we plan to categorise subjects in two groups for muscle function (eg, low and high muscle strength groups). The assumed incidence of cognitive decline per year is 1%--2% and the assumed cumulative incidence over 10 years in the population is 15%.[@R54] The low muscle function group was assumed to have a twofold higher risk of cognitive decline. Therefore, a sample of 1519 subjects was estimated to be necessary, assuming a drop-out rate of 15% over 10 years.

Since we also plan to perform a cross-sectional analysis using baseline data, we performed a preliminary sample size calculation. Although muscle mass, muscle strength and insulin sensitivity reflect different aspects of muscle function, the combined associations of these parameters with diseases or risk factors related to needing long-term care remain unclear. Thus, we plan to categorise subjects in nine categories of muscle function (eg, low, middle and high muscle strength ×low, middle and high insulin sensitivity) and focus on associations between these categories of muscle function and cognitive decline. We also plan to evaluate other outcomes such as arteriosclerosis, cerebral SVD, osteoporosis, knee joint condition, cognitive function, brain volume and structure, depression, and physical function in the cross-sectional analysis. We estimated that rates of cognitive decline in the group with higher muscle function to be 12%, compared with 24% in the group with lower muscle function.[@R50] A sample of 1584 subjects was estimated to be necessary based on statistical power of 80% at a significance level of 5%. Thus, the estimated required number of subjects in the cross-sectional analysis (1584) is sufficient for the prospective analysis. We set the overall sample size to be 1600 in the present study.

Participants {#s2-3}
------------

For the baseline examination (15 October 2015 to 1 October 2018), we mailed invitations to attend a group briefing session to all 8629 elderly individuals living in 13 communities in Bunkyo-ku, Tokyo, Japan, of whom 1984 (23.0%) subjects participated in a group briefing session at our institution (Sportology Center, Juntendo University). After the briefing session, 1830 subjects provided written informed consent for study participation. However, 190 subjects withdrew consent and 11 subjects were excluded based on age, pacemaker status and insulin therapy status. Ultimately, the study subjects comprised 1629 elderly people, which corresponds to 18.9% of all elderly individuals in 13 selected communities of Bunkyo-ku) ([figure 3](#F3){ref-type="fig"}).

![Flow chart of the participant recruitment process.](bmjopen-2019-031584f03){#F3}

Measurements {#s3}
============

Muscle mass and strength {#s3-1}
------------------------

Muscle mass was measured using DXA (Discovery DXA System, Hologic, Tokyo, Japan).[@R56] Skeletal Muscle Mass Index (SMI) was calculated by dividing appendicular muscle mass (kg) by height squared (m^2^).[@R57] Lower limb isokinetic muscle strength (angular velocity of 60°/s) was measured using a dynamometer (BIODEX system 3 or 4: Biodex Medical Systems, Upton, New York, USA).[@R58]

Insulin sensitivity {#s3-2}
-------------------

Insulin sensitivity was estimated with the Matsuda index using data on glucose and insulin during the 75 g OGTT.[@R46] The Matsuda index was calculated using the following equation: 10 000/square root of (fasting glucose x fasting insulin) x (mean glucose x mean insulin during OGTT).[@R59] This formula can estimate whole-body glucose disposal during the euglycemic insulin clamp. Skeletal muscle is the main organ absorbing glucose during the clamp.[@R30] Thus, the Matsuda index is a surrogate marker of insulin sensitivity, mainly reflecting insulin sensitivity in muscle. Our previous study using the two-step hyperinsulinemic euglycemic clamp technique demonstrated that the Matsuda index is significantly correlated with muscle insulin sensitivity, not hepatic insulin sensitivity.[@R31]

Cognitive function {#s3-3}
------------------

Cognitive function was primarily evaluated using the MoCA[@R36] and the MMSE.[@R37] The MoCA and MMSE contain 9 and 11 items, respectively. Possible scores range from 0 to 30 points. In this study, we used MoCA score ≤22 as the cut-off for MCI[@R60] and MMSE score ≤23 as the cut-off for dementia.[@R37] The Neurobehavioral Cognitive Status Examination, which evaluates orientation, attention, language, memory, calculation, construction and reasoning[@R62] the Trail Making Test, which evaluates visual-conceptual and visual-motor tracking[@R64] and the Wechsler Memory Scale-Revised (part Ⅱ)[@R66]were also used for evaluation of cognitive function. We also used the short version of the Geriatric Depression Scale[@R68] to assess depression, defined as a score ≥10 points.

Evaluation of whole brain MRI {#s3-4}
-----------------------------

We performed whole brain MR scanning with a 0.3 T clinical MR scanner (AIRIS Vento, Hitachi, Tokyo, Japan) in all participants. In addition, brain MR scanning was also performed in some participants on a 3 T clinical MR scanner (MAGNETOM Prisma, Siemens Healthcare, Erlangen, Germany) with a 64-channel head coil for advanced brain MRI analysis and validation of brain analysis with the 0.3 T clinical MR scanner.

The following sequences were obtained with the 0.3 T clinical MR scanner: axial three-dimensional (3D) time-of-flight MR angiography (repetition time (TR), 35 ms; echo time (TE), 7.1 ms and slice thickness, 1.2 mm), T2\*-weighted gradient echo imaging (TR, 1000 ms; TE, 45 ms; flip angle, 20° and slice thickness, 5 mm), and fluid-attenuated inversion recovery imaging (TR, 11 000 ms; TE, 100 ms; inversion time (TI), 2000 ms and slice thickness, 5 mm). We also obtained 3D-volumetric T1-weighted imaging using a gradient echo with inversion recovery sequence with these following parameters: TR, 25 ms; TE, 5.8 ms; TI, 600 ms; flip angle, 12°; number of excitations, 1; field of view (FOV), 200×250 × 250 mm^3^; resolution, 0.98×0.98 × 2 mm^3^; slice orientation, sagittal; total scan time, 10.1 min.

The protocol with the 3 T clinical MR scanner included 3D T1-weighted imaging and multishell diffusion weighted imaging (DWI). 3D T1-weighted images were obtained using magnetisation-prepared 180° radio frequency pulses and rapid gradient-echo with these following parameters: TR, 2300 ms; TE, 2.32 ms; TI: 900 ms; FOV, 240×240 mm; matrix size, 256×256; resolution, 0.9×0.9 mm; slice thickness, 0.9 mm and acquisition time, 5.21 min. For DWI, echo planar imaging (EPI) consisting of two b values (1000 and 2000 s/mm^2^) along 64 isotropic diffusion gradients was acquired in the anterior--posterior phase-encoding direction with the following parameters: TR, 3300 ms; TE, 70 ms; FOV, 229×229 mm; matrix size, 130×130; resolution 1.8×1.8 mm; slice thickness, 1.8 mm and acquisition time, 7.29 min. Each DWI acquisition was completed with a gradient-free image (b=0). We also acquired standard and reverse phase encoded blipped images with no diffusion weighting (blip-up and blip-down) to correct for magnetic susceptibility-induced distortions related to EPI acquisitions.

Primary brain MRI evaluation was conducted by an experienced neuroradiologist based on axial T2\*-WI and FLAIR images obtained on a 0.3 T MR scanner. The evaluation included cerebral SVD, characterised by lacunar infarcts, cerebral microhaemorrhages, PVHs and DSWMHs. PVHs and DSWMHs were categorised using the Fazekas scale.[@R70] In this study, level III was defined as cerebral SVD. In addition, whole brain volume, regional brain volume, regional cortical thickness, and white and grey matter integrity were also included on subsequent evaluations. Furthermore, 0.3 T and 3 T 3D T1-weighted images were used for the quantification of whole brain volume as well as regional cortical volume and thickness; multishell DWI was used for the quantification of white and grey matter integrity.

Lifestyle and physical activity levels {#s3-5}
--------------------------------------

We investigated lifestyle and physical activity levels using questionnaires. To evaluate sleeping status, we used the Pittsburgh Sleep Quality Index, which has seven components.[@R71] We evaluated exercise habits and physical activity levels with the International Physical Activity Questionnaire, which assesses different types of physical activity such as walking, moderate-intensity activities and vigorous-intensity activities.[@R73] We evaluated nutritional status using a brief-type self-administered diet history questionnaire, which contains 58 items about fixed portions and food types.[@R75] We evaluated mental status using the 12-Item Short Form Health Survey (Standard Japanese, Quality Metric, Lincoln, Rhode Island, USA).[@R77] In addition, the Instrumental Activities of Daily Living scale was used to estimate the ability to live independently.[@R78]

Physical fitness and function {#s3-6}
-----------------------------

We evaluated physical fitness and function based on muscle strength with a hand grip dynamometer (T. K. K. 5401, Takei Scientific Instruments, Niigata, Japan)[@R38] balance using the one-leg standing test, which measures the duration of one-leg standing with eyes open[@R39]; flexibility using the sit-and-reach test (T.K.K.5112, Takei Scientific Instruments)[@R40]; gait speed using the 10 m walking test[@R41] and combined motor function using the Timed Up and Go test, which measures the time it takes a participant to rise from an arm chair, walk 3 m, turn, walk back and sit down again.[@R42] In addition, locomotive functions were evaluated using the stand-up test, two-step test and a risk assessment on physical condition and lifestyle with 25 questions (Locomotive Challenge! Council, Japanese Orthopaedic Association, Tokyo, Japan).

Blood and urine analysis {#s3-7}
------------------------

Blood and urine samples were collected in the morning after an overnight fast. Subsequently, a standard 75 g OGTT was performed. Blood samples were obtained before and 30, 60, 90 and 120 min after ingesting 75 g of glucose to determine plasma glucose and serum insulin levels. Serum and plasma samples were sent to a commercial clinical laboratory (SRL, Tokyo, Japan). Biochemical analysis for each parameter in [table 1](#T1){ref-type="table"} was performed using standard methods. Urine samples were used for albumin and qualitative tests. Other exploratory measurements are being planned for each study.

###### 

Parameters for blood and urine analyses

  --------------------------------------- ------------------------------------------------
  Complete blood count\                   Phosphate\
  Glucose\                                Homocysteine\
  Insulin\                                Adiponectin\
  C-peptide\                              C reactive protein intact parathyroid hormone\
  HbA~*1*C~\                              25-hydroxy vitamin D\
  Triglyceride\                           Bone-specific alkaline phosphatase\
  High-density lipoprotein cholesterol\   Tartrate-resistant acid phosphatase 5b\
  Low-density lipoprotein cholesterol\    N-terminal probrain natriuretic peptide\
  Free fatty acids\                       Insulin-like growth factors-1\
  Aspartate aminotransferase\             Dehydroepiandrosterone sulfate\
  Alanine aminotransferase\               Free triiodothyronine\
  γ-Glutamyl transferase\                 Free thyroxine\
  Albumin\                                Thyroid stimulating hormone\
  Creatinine\                             Total testosterone
  Calcium                                 

  --------------------------------------- ------------------------------------------------

DNA extraction and genome-wide association study {#s3-8}
------------------------------------------------

Genomic DNA will be extracted from peripheral leucocytes. We plan to evaluate single nucleotide polymorphisms (SNPs) using an SNP array optimised for the Japanese or Asian population.[@R79] DNA extraction and genome-wide association study will be performed to identify genes associated with clinical characteristics, mainly selected from the primary, secondary and exploratory outcomes.

Bone mineral density {#s3-9}
--------------------

BMD of the lumbar spine and femoral neck were measured using DXA (Discovery DXA System, Hologic). Quality assurance for longitudinal evaluation was performed by calibrating the machine with standardised phantoms. The coefficient of variation for the in vivo lumbar spine-BMD measurements was \<1%.[@R43] The diagnosis of osteoporosis was based on the criteria proposed by the Japanese Society of Bone and Mineral Metabolism in 2012.[@R80] Postmenopausal women were diagnosed with osteoporosis if they met the following criteria: ≥1 prevalent non-traumatic radiographic vertebral fractures based on clinical radiological criteria; hip fracture; low BMD (≤70% of the young adult mean value); and BMD ≤80% of the young adult mean value and ≥1 prevalent non-traumatic fragility fractures that are not vertebral or hip fractures.

Arteriosclerosis {#s3-10}
----------------

Arteriosclerosis was estimated using CAVI and the Ankle Brachial Index (ABI), which were measured using an automatic waveform analyzer (Vascular Screening System VaSera VS-1500, Fukuda Denshi, Tokyo, Japan).[@R44] Recording was performed in the supine position after 10 min of rest. Occlusion and monitoring cuffs were placed snugly on the upper and lower extremities. Pressure waveforms were then recorded simultaneously from the brachial arteries using the oscillometric method. All scans were automatically conducted by well-trained investigators. A resting ABI ≤0.90 was considered to reflect the presence of peripheral artery disease.

Abdominal fat area {#s3-11}
------------------

Intra-abdominal fat area was measured with a 0.3 T MR scanner (AIRIS Vento, Hitachi). Subjects were in the prone position in the magnet with their arms placed straight overhead. Using the intervertebral space between the fourth and fifth lumbar vertebrae (L4--L5) as the point of origin, transverse images of 10 mm slice thickness were obtained every 100 mm from head to foot, resulting in a total of 10 images for each subject. All MRI data were transferred to a computer workstation for analysis using specialised image analysis software (AZE Virtual Place, AZE, Tokyo, Japan) to measure visceral and subcutaneous fat area.

Anthropometric measurement {#s3-12}
--------------------------

Height was measured within 0.1 cm using a stadiometer in the upright position in the morning. Body weight was measured within 0.1 kg using an electronic scale (InBody770; Biospace, Seoul, Korea). Circumference of the waist as well as the thigh and calf of the dominant leg were measured within 0.5 cm with a plastic tape measure.

Evaluation of osteoarthritis of the knee joint and knee pain {#s3-13}
------------------------------------------------------------

Radiographic OA severity[@R81] was evaluated using the Kellgren-Lawrence grading system based on weight-bearing anteroposterior radiographs of the femorotibial joint for both knees in the bilateral standing extended view as well as weight-bearing posteroanterior radiographs of the femorotibial joint with the knee in 45° of flexion.

Knee joints were also examined with MRI. Imaging sequences included coronal and sagittal proton density-weighted images with or without fat suppression and T2 mapping. Morphological changes in knee OA were semiquantitatively evaluated according to the Whole Organ MRI Score.[@R82] Medial meniscus extrusion was also evaluated, we previously described[@R83]

Clinical manifestations of knee pain were evaluated using a Visual Analogue Scale of 0--100 mm and the Japanese Knee Osteoarthritis Measure (JKOM) score.[@R87] JKOM is a self-reported score that includes four subcategories: pain and stiffness (0--32 points), activities of daily living (0--40 points), social activities (0--20 points) and general health condition (0--8 points), with 100 points being the maximum score.

Patient and public involvement {#s3-14}
------------------------------

No participants were involved in development of the research questions, design of the study or the recruitment.

Statistical analysis {#s3-15}
--------------------

Statistical analyses are planned to evaluate associations between muscle function and clinical outcomes. We use regression analysis with adjustment for age, sex and other potential factors, appropriately. Sex will be stratified as male and female. Age brackets will be 65--69, 70--74, 75--79 and 80--84 years. The follow-up period is defined as the time from the baseline examination to the occurrence of each event during follow-up examinations. In addition, exploratory analyses will be performed with several exposures and outcomes. Statistical analysis plans will be appropriate to each study.

Findings to date {#s3-16}
----------------

The cohort was similar to the population of Bunkyo-ku and Tokyo, respectively ([figure 4](#F4){ref-type="fig"}). This cohort characteristics was shown in [table 2](#T2){ref-type="table"}. Average age was 73.1±5.4 years (males: 73.0±5.3, female: 73.2±5.4). The male:female ratio was 0.73:1 (males: n=687, 42.2%; females: n=942, 57.8%), which was also similar to that of Bunkyo-ku and Tokyo, respectively. The MoCA and MMSE scores for cognitive function were 25.1±3.0 and 27.7±1.9, respectively. Subjects with MCI (MoCA score ≤22) and dementia (MMSE score ≤23) represented 18.1% and 3.3% of the study cohort, respectively. The prevalence of MCI, dementia, hypertension and diabetes was comparable to the prevalence for those conditions in a similar elderly Japanese cohort.[@R88] There were 402 participants (24.8%) with cerebral SVD, which was also similar to the results of a previous study.[@R49]

![Distribution of the elderly population in this cohort, Bunkyo-ku and Tokyo. The proportion of elderly individuals in each age group (age 65--84 years) in this cohort, Bunkyo-ku and Tokyo are presented.](bmjopen-2019-031584f04){#F4}

###### 

Characteristics of study subjects

  N                                                  All participants   Male         Female
  -------------------------------------------------- ------------------ ------------ ------------
  Age (years old)                                    73.1±5.4           73.0±5.3     73.2±5.4
  Height (cm)                                        158.0±8.8          165.8±5.9    152.4±5.6
  Body weight (kg)                                   58.2±10.4          65.7±8.6     52.7±7.7
  Body mass index (kg/m^2^)                          23.2±3.1           23.9±2.8     22.7±3.2
  Education (year)                                   13.9±2.5           14.9±2.5     13.2±2.2
  Worker/volunteer (n; %)                            563 (34.6)         288 (41.9)   275 (29.2)
  Needing long-term care (n; %)                      27 (1.7)           14 (2.0)     13 (1.4)
  Solitude (n; %)                                    342 (21.0)         84 (12.2)    258 (27.4)
  Hypertension (n; %)                                748 (45.9)         368 (53.6)   380 (40.3)
  Diabetes (n; %)                                    187 (11.5)         113 (16.4)   74 (7.9)
  Dyslipidemia (n; %)                                639 (39.2)         231 (33.6)   408 (43.3)
  Cerebrovascular disease (n; %)                     68 (4.2)           34 (4.9)     34 (3.6)
  Cardiovascular disease (n; %)                      75 (4.6)           50 (7.3)     25 (2.7)
  Cancer (n; %)                                      40 (2.5)           25 (3.6)     15 (1.6)
  Cerebral small vessel disease (n; %)               402 (24.8)         178 (26.1)   224 (23.9)
  Systolic blood pressure (mm Hg)                    136.6±17.1         136.8±16.4   136.5±17.6
  Diastolic blood pressure (mm Hg)                   84.3±9.8           86.4±9.7     82.8±9.5
  Cardio Ankle Vascular Index: Right                 9.0±1.1            9.2±1.1      8.8±1.1
  Cardio Ankle Vascular Index: Left                  8.9±1.1            9.1±1.0      8.7±1.0
  Skeletal muscle mass (kg/m^2^)                     7.1±1.1            7.9±0.9      6.5±0.8
  Muscle isokinetic strength (Nm/kg)                 133.2±37.5         148.4±38.8   122.2±32.3
  Hang-grip strength (kg)                            25.9±7.1           32.3±5.7     21.2±3.5
  Gait speed (m/sec)                                 1.9±0.4            2.0±0.4      1.8±0.3
  Timed up and Go test (sec)                         6.7±1.6            6.5±1.6      6.8±1.5
  Instrumental Activities of Daily Living (point)    6.7±1.5            5.0±0.3      8.0±0.2
  Depression: GDS ≥10 point (n; %)                   31 (1.9)           15 (2.2)     16 (1.7)
  Fasting plasma glucose (mg/dL)                     100.5±16.7         104.5±18.2   97.6±14.8
  Fasting plasma insulin (μU/mL)                     4.9±3.3            5.0±3.4      4.8±3.2
  HbA1c (%)                                          5.8±0.6            5.9±0.6      5.8±0.5
  Triglycerides (mg/dL)                              98.5±54.2          104.5±60.6   94.1±48.6
  HDL cholesterol (mg/dL)                            64.3±16.5          58.7±15.7    68.4±16.0
  LDL cholesterol (mg/dL)                            121.3±30.8         113.8±30.7   126.8±29.7
  Aspartate aminotransferase (IU/L)                  23.5±9.5           23.6±9.4     23.4±9.6
  Alanine aminotransferase (IU/L)                    19.3±11.1          20.4±12.4    18.5±10.1
  γ-glutamyl transferase (IU/L)                      30.8±35.8          40.3±49.5    23.8±17.8
  Serum albumin (g/dL)                               4.3±0.4            4.3±0.4      4.3±0.4
  Creatinine (mg/dL)                                 0.8±0.3            0.9±0.4      0.7±0.2
  Matsuda index                                      7.3±4.1            7.4±4.6      7.2±3.7
  Montreal Cognitive Assessment (MoCA) (point)       25.1±3.0           24.7±3.0     25.5±3.0
  Mild Cognitive Impairment: MoCA ≤22 point (n; %)   295 (18.1)         152 (22.1)   143 (15.2)
  Mini-Mental State Examination (MMSE) (point)       27.7±1.9           27.5±2.0     27.9±1.9
  Dementia: MMSE ≤23 point (n; %)                    53 (3.3)           23 (3.3)     30 (3.2)
  Bone mineral density of the femoral neck (g/cm²)   0.6±0.1            0.7±0.1      0.6±0.1
  Bone mineral density of the lumbar spine (g/cm²)   0.9±0.2            1.1±0.2      0.8±0.2

In terms of muscle function, SMIs in males and females were 7.9±0.9 kg/m^2^ and 6.5±0.8 kg/m^2^, respectively. Muscle isokinetic strength was 148.4±38.8 Nm/kg in males and 122.2±32.3 Nm/kg in females. These findings are comparable to values in elderly Japanese subjects.[@R88] Insulin sensitivity estimated using the Matsuda index was 7.3±4.1, which is similar to the value in non-obese, non-diabetic and middle-aged men.[@R31]

Strengths and limitations {#s3-17}
-------------------------

Strengths of the present study include: (1) long-term prospective cohort study design to identify risk factors for needing long-term care, (2) random sampling of elderly individuals in an urban area, (3) assembly of a relatively large cohort for evaluating muscle mass, muscle strength and insulin sensitivity, whole brain MRI, cognitive function, vascular function, physical fitness and knee OA simultaneously. Therefore, this study can evaluate relationships between muscle mass, muscle strength, and insulin sensitivity and multiple diseases that lead to needing long-term care. This study may suggest novel strategies to prevent the need for long-term care.

This study has several limitations such as (1) including only participants living in an urban part of Japan, (2) challenges in confirming causal relationships and (3) a relatively low participation rate (18.9%), thus, we cannot deny the possibility of selection bias and we should be careful about the interpretation of the results. Before subject recruitment, we recognised that the participation rate in a similar study conducted in Japan was low (18.4%).[@R91] Thus, we sent invitation letters twice after no initial reply and called the subjects before the briefing session to increase the participation rate. Other plans may be considered to further increase the participation rate in future studies of community dwelling.

Collaborators {#s3-18}
-------------

For more information or potential collaboration, please contact Yoshifumi Tamura (ys-tamur\@juntendo.ac.jp) and Yuki Someya (yksomeya\@juntendo.ac.jp).

Ethics and dissemination {#s4}
========================

All participants gave written informed consent at the orientation meeting. Participants were told that they have the right to withdraw from the trial at any time. Data are coded and stored securely in password-protected files. Only the principal investigators have access to the files. The findings of the study will be presented in local and international conferences and disseminated in peer-reviewed journals.
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